Needham & Company LLC Reaffirms “Strong-Buy” Rating for Bruker (BRKR)

Bruker (NASDAQ:BRKR)‘s stock had its “strong-buy” rating reiterated by stock analysts at Needham & Company LLC in a research note issued to investors on Monday, May 6th, MarketBeat reports. They presently have a $46.00 price objective on the medical research company’s stock, up from their previous price objective of $39.00. Needham & Company LLC’s price objective would suggest a potential upside of 10.92% from the company’s previous close.

Other equities analysts have also recently issued research reports about the company. Zacks Investment Research cut Bruker from a “strong-buy” rating to a “hold” rating in a report on Monday, January 7th. BTIG Research restated a “buy” rating and set a $44.00 price objective (up previously from $42.00) on shares of Bruker in a report on Tuesday, February 12th. BidaskClub upgraded Bruker from a “hold” rating to a “buy” rating in a report on Friday, January 11th. Deutsche Bank upgraded Bruker from a “hold” rating to a “buy” rating and boosted their price objective for the company from $40.00 to $50.00 in a report on Friday, April 12th. Finally, ValuEngine upgraded Bruker from a “hold” rating to a “buy” rating in a report on Tuesday, January 15th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $43.71.

NASDAQ:BRKR traded up $0.33 during trading hours on Monday, reaching $41.47. The stock had a trading volume of 520,819 shares, compared to its average volume of 733,164. The company has a debt-to-equity ratio of 0.42, a current ratio of 2.12 and a quick ratio of 1.27. Bruker has a 52 week low of $26.10 and a 52 week high of $44.47. The company has a market cap of $6.70 billion, a price-to-earnings ratio of 29.62, a PEG ratio of 2.27 and a beta of 1.44.

Bruker (NASDAQ:BRKR) last released its quarterly earnings data on Thursday, May 2nd. The medical research company reported $0.28 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.24 by $0.04. Bruker had a return on equity of 26.28% and a net margin of 9.53%. The business had revenue of $461.40 million for the quarter, compared to the consensus estimate of $450.46 million. During the same quarter in the previous year, the company posted $0.24 EPS. The company’s revenue was up 6.9% compared to the same quarter last year. As a group, analysts anticipate that Bruker will post 1.61 EPS for the current year.

In other news, Director Marc A. Kastner sold 1,374 shares of the stock in a transaction dated Wednesday, May 15th. The stock was sold at an average price of $41.79, for a total value of $57,419.46. Following the transaction, the director now directly owns 10,811 shares of the company’s stock, valued at $451,791.69. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 26.50% of the stock is currently owned by corporate insiders.

Several institutional investors and hedge funds have recently modified their holdings of the company. O Shaughnessy Asset Management LLC purchased a new position in Bruker during the first quarter worth approximately $35,000. NumerixS Investment Technologies Inc boosted its position in Bruker by 150.0% during the first quarter. NumerixS Investment Technologies Inc now owns 1,000 shares of the medical research company’s stock worth $38,000 after purchasing an additional 600 shares in the last quarter. Hanseatic Management Services Inc. boosted its position in Bruker by 52.0% during the fourth quarter. Hanseatic Management Services Inc. now owns 1,692 shares of the medical research company’s stock worth $50,000 after purchasing an additional 579 shares in the last quarter. Captrust Financial Advisors boosted its position in Bruker by 164.7% during the fourth quarter. Captrust Financial Advisors now owns 1,824 shares of the medical research company’s stock worth $54,000 after purchasing an additional 1,135 shares in the last quarter. Finally, Rockefeller Capital Management L.P. purchased a new position in Bruker during the first quarter worth approximately $67,000. Hedge funds and other institutional investors own 66.74% of the company’s stock.

Bruker Company Profile

Bruker Corporation manufactures and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates in two segments, Bruker Scientific Instruments, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry solutions; infrared spectroscopy and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection in emergency response, homeland security, and defense applications; and research, analytical, and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies.

Read More: What is Cost of Capital?

Analyst Recommendations for Bruker (NASDAQ:BRKR)

Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.